The honest answer depends on which ADHD medication you mean and which state you’re in, and the rules for New Jersey and New York aren’t currently the same. This isn’t a minor technicality. For stimulant medications specifically, New Jersey now requires something New York currently doesn’t, and the rule changed as recently as February 2026.
If you’ve started researching ADHD telehealth and found conflicting information, that’s not you misreading something. The federal government, New Jersey, and New York each have their own layer of rules, and they don’t all say the same thing. This article walks through what each layer actually requires, why the rules exist in the first place, and what it practically means depending on where you live and which medication you’re likely to need.
The short answer
Non-stimulant ADHD medications, atomoxetine (Strattera), viloxazine (Qelbree), guanfacine ER (Intuniv), and bupropion used off-label, aren’t controlled substances, so none of this applies to them. They can be prescribed by telehealth in both NJ and NY without any special in-person requirement tied to controlled-substance law.
Stimulant medications, methylphenidate-based (Ritalin, Concerta, Focalin) and amphetamine-based (Adderall, Vyvanse, Mydayis), are Schedule II controlled substances, the most tightly regulated prescription drug category, and that’s where New Jersey and New York currently diverge.
Why this is confusing: three layers of rules, not one
Federal law sets a floor. States can require more, but not less. For controlled substance telehealth prescribing specifically, that’s exactly what’s happening right now: the federal government has temporarily waived its usual in-person requirement, but New Jersey has its own, stricter state rule that applies regardless of what the federal government currently allows. New York, meanwhile, has written its rule to simply follow whichever of state or federal law is in force. Three layers, three different postures, and only one of them currently adds friction.
The federal baseline: a temporary DEA waiver, not a permanent rule
The underlying federal law, the Ryan Haight Online Pharmacy Consumer Protection Act of 2008, normally requires a prescriber to conduct an in-person medical evaluation before prescribing a Schedule II through V controlled substance by telemedicine. It was written specifically to shut down online pill mills that were prescribing controlled substances to patients a doctor had never actually examined. Since the COVID-19 public health emergency, the DEA and HHS have repeatedly issued temporary extensions waiving that in-person requirement. The current one, the fourth extension, runs through December 31, 2026, and allows prescribing Schedule II through V medications via audio-video telehealth without a prior in-person visit, for new and existing patients alike. Audio-only calls don’t qualify for stimulant prescribing under this waiver; the visit has to be video.
This is the piece that gets reported as “telehealth ADHD prescriptions are allowed,” and federally, as of this writing, that’s accurate. But it’s a temporary extension renewed roughly once a year while DEA and HHS work on a permanent rule, not a settled policy, and states are free to layer stricter requirements on top of it, which is exactly what New Jersey has now done.
New Jersey’s rule is stricter than the federal baseline
Effective February 16, 2026, New Jersey’s own telemedicine statute requires an initial in-person medical examination before a Schedule II controlled substance can be prescribed via telemedicine, and an in-person visit at least once every three months after that, for as long as the prescription continues. This is a state-level requirement that applies in New Jersey regardless of the federal waiver being in effect. Practically, if you’re in NJ and need a stimulant medication for ADHD, the first visit needs to happen in person, and periodic in-person follow-up is part of ongoing care, not an optional add-on.
The three-month cadence matters for planning purposes. It doesn’t mean every single follow-up visit has to be in person, it means that across any rolling three-month window, at least one visit needs to be. Most practices build their follow-up schedule around that rhythm anyway, since regular monitoring of dose, side effects, and response is standard practice for stimulant medication regardless of what the law requires.
New York currently follows the federal flexibility
New York finalized its own controlled-substance telemedicine regulation in 2025, but rather than imposing an independent in-person mandate, it ties compliance to whichever of state or federal law applies. Since the federal waiver is currently in effect through the end of 2026, New York prescribers can currently rely on it for Schedule II prescribing by telehealth, alongside New York’s standing requirement to check the state’s Prescription Monitoring Program before prescribing. That’s a real, current difference from New Jersey, not a technicality, and it’s worth knowing if you’re comparing care options across the two states.
Why these rules exist in the first place
It’s worth understanding the backdrop, because it explains why regulators have gotten more careful rather than less. In 2022 and after, several venture-backed telehealth startups built business models almost entirely around fast ADHD diagnoses and stimulant prescriptions, often with minimal evaluation and little to no ongoing monitoring. Some of those companies, most visibly Cerebral and Done, came under federal investigation and DEA scrutiny for prescribing practices that looked less like careful psychiatric care and more like volume-driven stimulant dispensing. That enforcement environment is part of why New Jersey tightened its own rule rather than simply continuing to lean on the federal waiver indefinitely, and it’s a useful lens for evaluating any telehealth ADHD provider, not just the rules themselves.
How to tell a careful evaluation from a corner-cutting one
A few signs are worth watching for regardless of which state you’re in. A legitimate evaluation takes real time, generally 45 to 60 minutes, not five to ten, and covers symptom history, prior treatment, and conditions that can look like ADHD but aren’t. A provider should ask about your full psychiatric history, not just run through an ADHD checklist. Same-day prescribing with no real evaluation, or a diagnosis that arrives before you’ve actually described your symptoms in any depth, is a red flag regardless of the state’s specific telehealth rules. And ongoing monitoring, actual follow-up visits where dose and response get reviewed, should be part of the plan from the start, not something you have to ask for later.
What this actually means if you’re starting ADHD telehealth treatment
If a non-stimulant is the right fit, none of this applies, and telehealth works the same way in both states. If a stimulant is likely the right medication, which is common given how effective they are for most adults with ADHD, the practical path currently looks different depending on where you live. In New Jersey, plan on an in-person first visit and periodic in-person follow-ups if you end up on a stimulant. In New York, telehealth can currently cover the full relationship, including the first visit, for a stimulant prescription, though that could change if New York’s rule shifts or the federal waiver isn’t extended again. This is also exactly why an accurate diagnosis matters before any of this becomes relevant. The distinction between needing a full ADHD evaluation versus formal testing, and what that evaluation actually involves, is covered in a separate post if you haven’t gone through that step yet.
What if you already started with a telehealth-only provider before February 2026?
If you’re an existing New Jersey patient who began stimulant treatment with a telehealth-only provider before the state’s rule took effect, the three-month in-person requirement still applies going forward. It’s not retroactive in the sense of invalidating your existing diagnosis or treatment plan, but any practice prescribing to you in New Jersey now needs to get you in for an in-person visit within that rolling window to stay compliant. If your current provider operates telehealth-only with no in-person option at all, that’s worth asking about directly, since it may affect whether they can continue your prescription under the new rule.
Why an in-person first visit isn’t actually a setback
For a new ADHD diagnosis specifically, there’s a clinical argument for an in-person first visit that has nothing to do with the regulation: it’s simply easier to pick up on things like comorbid anxiety, mood symptoms, or physical signs worth noting when you’re in the room together, and New Jersey’s rule now makes that the default rather than an option. For follow-up visits once a diagnosis and medication plan are established, telehealth remains a genuinely convenient way to keep the regular monitoring that stimulant medication requires, dosage checks, side effect review, and refill continuity, without a commute every time. The in-person requirement and telehealth convenience aren’t really in tension once you look at where each one actually fits.
These rules are temporary, and they’re worth rechecking
Every part of this is built on extensions and interim rules, not permanent law. The federal flexibility has already been extended four times and is scheduled to run through December 31, 2026, with a permanent rule still pending. New Jersey’s stricter rule only took effect in February 2026. None of this is settled enough to treat as fixed. If you’re reading this well after publication, it’s worth confirming the current status rather than assuming it hasn’t changed.
Where this leaves you
If you’re in New Jersey or New York and want to know what ADHD telehealth actually looks like for your situation, that’s exactly what a discovery call is for. I provide ADHD evaluation and medication management for patients across both states, in person at my Fort Lee office and via telehealth, and I’ll walk you through what applies to your specific medication and location before you book anything. For background on how this landscape developed for ADHD prescribing specifically, a related post covers who can actually prescribe ADHD medication in NJ and NY and why that question gets complicated.
For the authoritative federal source on telemedicine controlled-substance rules, the American Psychiatric Association’s telepsychiatry toolkit maintains current guidance on the Ryan Haight Act and the DEA’s telemedicine flexibilities.
